Department of Pharmacy, Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, Japan.
Department of Pharmacy, Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, Japan.
Eur J Pharm Sci. 2018 Jan 15;112:132-138. doi: 10.1016/j.ejps.2017.11.018. Epub 2017 Nov 22.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause idiosyncratic liver injury. Mechanisms involved in NSAID-induced liver injury are complex. Previous studies have suggested that acyl glucuronide of NSAIDs (NSAIDs-Glu) plays an important role in the development of liver injury via covalently binds to proteins and the resultant adduct induces immunological toxicity. As only some NSAIDs-Glu are commercially available, the evaluation of covalent protein adduct formation using ready-made NSAIDs-Glu is difficult and inconvenient. Moreover, glucuronidation potency varies with the NSAID, including stereoisomers. Therefore, in this study, we simultaneously examined the glucuronidation and covalent adduct formation using enantiomers of parent NSAIDs (ibuprofen, naproxen, pranoprofen, ketoprofen, and flurbiprofen) in rat liver microsomes. Glucuronides and covalent adducts were quantified by HPLC. The amount of covalent adduct increased with NSAIDs-Glu formation in the rat liver microsomes in a time-dependent manner. A significant positive correlation was observed between the AUC of NSAIDs-Glu and that of covalent adduct, except ketoprofen. Although ketoprofen exhibited the highest glucuronidation rate among the NSAIDs investigated, the amount of covalent adduct was similar to that for pranoprofen, which had the lowest glucuronidation rate. Thus, it may be difficult for ketoprofen glucuronide to covalently bind with proteins in the rat liver microsomes. Our results suggested that the amount of glucuronide formed is a key factor in predicting covalent bond formation with protein in NSAIDs, in addition to degradability and bindability with proteins of NSAIDs-Glu. Further studies are required to confirm the relationship between the tendency of glucuronidation and the formation of covalent adducts of NSAIDs.
非甾体抗炎药 (NSAIDs) 可导致特异质肝损伤。涉及 NSAID 诱导肝损伤的机制很复杂。先前的研究表明,NSAIDs 的酰基葡萄糖醛酸 (NSAIDs-Glu) 通过与蛋白质共价结合在肝损伤的发展中起重要作用,而由此产生的加合物引起免疫毒性。由于只有一些 NSAIDs-Glu 可商购获得,因此使用现成的 NSAIDs-Glu 评估共价蛋白加合物的形成既困难又不方便。此外,葡萄糖醛酸化能力因 NSAID 而异,包括立体异构体。因此,在这项研究中,我们同时使用大鼠肝微粒体中的母体 NSAIDs(布洛芬、萘普生、普拉洛芬、酮洛芬和氟比洛芬)的对映异构体检查了葡萄糖醛酸化和共价加合物的形成。通过 HPLC 定量测定葡萄糖醛酸苷和共价加合物。在大鼠肝微粒体中,共价加合物的量随 NSAIDs-Glu 的形成而呈时间依赖性增加。除酮洛芬外,NSAIDs-Glu 的 AUC 与共价加合物的 AUC 之间观察到显著的正相关。尽管在研究的 NSAIDs 中,酮洛芬表现出最高的葡萄糖醛酸化速率,但共价加合物的量与具有最低葡萄糖醛酸化速率的普拉洛芬相似。因此,酮洛芬葡萄糖醛酸可能难以与大鼠肝微粒体中的蛋白质共价结合。我们的结果表明,形成的葡萄糖醛酸苷的量是预测 NSAIDs 中与蛋白质形成共价键的关键因素,除了 NSAIDs-Glu 的降解性和与蛋白质的结合能力之外。需要进一步的研究来确认 NSAIDs 的葡萄糖醛酸化倾向与共价加合物形成之间的关系。